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Vertically aligned carbon nanotube array (VANTA) coatings have recently garnered much attention due in
part to their unique material properties including light absorption, chemical inertness, and electrical
conductivity. Herein we report the first use of VANTAs grown via chemical vapor deposition in a 2D
interdigitated electrode (IDE) footprint with a high height-to-width aspect ratio (3:1 or 75:25 µm). The
VANTA-IDE is functionalized with an antibody (Ab) specific to the human cancerous inhibitor PP2A
(CIP2A)—a salivary oncoprotein that is associated with a variety of malignancies such as oral, breast, and
multiple myeloma cancers. The resultant immunosensor is capable of detecting CIP2A label-free across a wide
linear sensing range (1 –100 pg/mL) with a detection limit of 0.24 pg/mL within saliva supernatant—a range
that is more sensitive than the corresponding CIP2A enzyme linked immunosorbent assay (ELISA). These
results help pave the way for rapid cancer screening tests at the point-of-care (POC) such as for the early-stage
diagnosis of oral cancer at a dentist's office.
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Abstract 
Vertically aligned carbon nanotube array (VANTA) coatings have recently garnered 
much attention due in part to their unique material properties including light absorption, 
chemical inertness, and electrical conductivity. Herein we report the first use of VANTAs grown 
via chemical vapor deposition in a 2D interdigitated electrode (IDE) footprint with a high height-
to-width aspect ratio (3:1 or 75:25 µm).  The VANTA-IDE is functionalized with an antibody 
(Ab) specific to the human cancerous inhibitor PP2A (CIP2A)—a salivary oncoprotein that is 
associated with a variety of malignancies such as oral, breast, and multiple myeloma cancers.  
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The resultant immunosensor is capable of detecting CIP2A label-free across a wide linear 
sensing range (1 –100 pg/mL) with a detection limit of 0.24 pg/mL within saliva supernatant—a 
range that is more sensitive than the corresponding CIP2A enzyme linked immunosorbent assay 
(ELISA).  These results help pave the way for rapid cancer screening tests at the point-of-care 
(POC) such as for the early-stage diagnosis of oral cancer at a dentist’s office.    
Table of Content (ToC) Image  
  
 
 
Description: (Left) Schematic diagram showing antibody functionalized (anti-CIP2A) vertically 
aligned carbon nanotubes (VANTAs) arrayed in an interdigitated electrode (IDE) footprint. (Left 
Inset) An optical image of a VANTA IDE immunosensor fabricated on silicon wafer. (Right) 
Electrochemical impedance sensing of CIP2A antigen concentrations with the biofunctionalized 
VANTA IDEs.  
 
 
Keywords:  carbon nanotubes, chemical vapor deposition, point-of-care diagnostics, 
immunosensor, cancer, CIP2A 
 
1. Introduction 
Oral cancers (OCs) are the thirteenth most common cancers in the world with approximately 
300,000 new cases and 145,000 deaths annually(M.Merzianu, 2017). Despite occurring in one of 
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the most accessible anatomical sites of the human body, early diagnosis of OC is challenging as 
70% of oral malignancies are diagnosed in advanced stages (Sankaranarayanan et al., 2010). 
Hence, the prognosis of OC patients is generally poor as the overall 5-year survival rate for OCs 
is less than 40% (Lingen et al., 2008). In an effort to improve prognosis, a wide variety of OC 
screening techniques have been developed including visual screening (Lingen et al., 2008), 
toluidine blue (TB) staining (Patton et al., 2008), auto-fluorescence spectroscopy(Richards-
kortum and Sevick-muraca, 1996), exfoliative cytology (Lingen et al., 2008), and 
biopsy/histopathology (M.Merzianu, 2017). However, these techniques suffer from issues such 
as low sensitivity, lack of specificity for malignant tissue, and are also time-consuming, 
expensive, and labor intensive (M.Merzianu, 2017).  
Electrochemical-based biosensors comprised of interdigitated electrodes (IDEs) and 
monitored with electrochemical impedance spectroscopy (EIS) may hold the key to point-of-care 
cancer diagnostics (Chikkaveeraiah et al., 2012; Medina-Sánchez et al., 2016; Yang et al., 2004).  
IDEs consist of alternating ‘finger-like’ electrodes that are electrically connected with a width 
and pitch typically in the range of 5 – 25 m (Fowler et al., 2009; Xiuting Li et al., 2017).  IDEs 
inherently operate well as electrochemical transducers as they exhibit low ohmic drops, large 
collection efficiencies, high signal-to-noise ratios, and fast response times (Bratov et al., 2008; 
Kokkinos et al., 2016; Varshney et al., 2007; Yang et al., 2004). EIS is often employed as the 
sensing modality for IDE-based immunosensors due to its ability to detect small variations in 
resistance/capacitance which offers the potential for label-free, real-time, and in situ detection of 
various analytes (Bratov et al., 2008).  Moreover, electrochemical IDEs have recently shown 
tremendous promise in detecting cancer linked proteins with low detection limits and wide 
sensing ranges [e.g., 0.1 ng/mL to 1000 ng/mL for carcinoembryonic antigen (CEA) (Xueqin Li 
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et al., 2017), 0.01 to 100 ng/mL for human immunoglobulin A (IgA) (Ohno et al., 2013), and 1.0 
pg/L to 1.0 μg/L for prostate specific antigen (Huang et al., 2009)].  Although these reported 
IDE-based immunosensors circumvent much of the laboratory expertise and time associated with 
conventional immunoassay-based tests (Lequin, 2005), they typically require the use of a 
secondary Ab label conjugated with either a conductive nanoparticle or enzyme-nanoparticle 
bioconjugate. Such labeling techniques are utilized to amplify the heterogeneous charge transport 
at the sensor-liquid interface, because of the relatively insulating qualities of the biorecognition 
agents themselves and/or the surface functionalization motifs (Bogomolova et al., 2009; 
Jonathan C. Claussen et al., 2011; Pei et al., 2001). Consequently, such labeling requirements 
increase the complexity of the biosensing protocol and diminish the likelihood of point-of-care 
(POC) testing.  
Herein we report, the first EIS IDE immunosensor for a biomarker related to oral cancer, 
viz., CIP2A, as well as to malignancies such as breast cancer and multiple myeloma (Katz et al., 
2010a; Paluszczak et al., 2015).  The oncoprotein CIP2A promotes malignant cell growth and 
tumor progression and is generally overexpressed in most human cancers including lung, breast 
and gastric cancers (Haesen et al.,2012; Junttila et al.,2007; Kast et al., 2015; Khanna et al., 
2009; Côme et al., 2009; Don et al.,2011) However, CIP2A expression is more pronounced in 
oral cancers as compared to lung and gastric cancers with 85% of tongue cancer specimens (Katz 
et al., 2010b)  and 90% of esophageal squamous cell carcinoma the specimens (Qu et al., 2010).  
scoring moderately or strongly positive. Moreover, CIP2A is abundantly expressed in oral 
squamous cell carcinoma lines as well as dysplastic and malignant human oral epithelial tissues 
(Ahola et al., 2007; Basile et al., 2017; Yu et al., 2014).  Therefore, the developed CIP2A 
biosensor could be of significant value towards the development of an oral cancer screening test. 
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The immunosensor developed in this work is the first to use 3D high-aspect-ratio 
vertically aligned carbon nanotube arrays (VANTAs) arranged in a 2D IDE footprint to enable 
rapid, label-free CIP2A monitoring. The high surface area of the VANTA IDEs and favorable 
materials properties of carbon nanotubes (CNTs) (e.g., high electrical conductivity, 
electrochemical reactivity, and biocompatibility)(Claussen et al., 2009; Wang, 2005; Wang and 
Musameh, 2003) leads to a higher biosensor sensitivity than a comparable ELISA test kit.  
Moreover, the IDE designs requires facile lithographic patterning to create the CNT seed catalyst 
metal within a micro IDE pattern. Such patterning requires significantly reduced cleanroom 
processing than other immunosensors such as field effect transistors (FETs) that require 
nano/microwire gate development, gate oxide growth, deposition of active source/drain regions, 
reference electrode deposition, and passivation layer formation (Ding et al., 2017; de 
Vasconcelos et al., 2009).  Furthermore, cracks in the passivation layer of FETs can significantly 
alter biosensor outputs leading to false positive/negative signals. The use of IDEs in conjunction 
with an electrochemical sensing modality also eli inates t e need for target anal te la eling 
 it  fl orop ores or   rster resonance energ  transfer        d e pairs that are difficult to 
characterize and highly variable with in-field biological and/or turbid samples (Ding et al., 2015; 
Downing et al., 2012; Piston and Kremers, 2007) as well as the need for pre-enrichment steps 
that require upwards of 24–48 hours before biosensor signal acquisition as is the case with many 
lateral flow assayed immunosensors (Brodsky et al., 2011; Piston and Kremers, 2007; Poltronieri 
et al., 2014).  Moreover, electrochemical sensing yields a qualitative signal that can report a 
specific target analyte concentration as opposed to many colorimetric biosensors that report only 
qualitative results (Grieshaber et al., 2008; Lee et al., 2010).   Hence, the developed CIP2A 
biosensors are highly conducive to in-field POC diagnostics. 
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2. Results and discussion 
2.1 Fabrication and electrochemical characterization of VANTA IDE 
The VANTA IDEs were developed on silicon/silicon oxide wafers coated with an 
aluminum oxide (Al2O3) layer (Figure 1 & Supplemental Information).  Briefly, a thin (~ 7 
nm) iron catalytic layer was patterned in an IDE arrangement (10 fingers per electrode with each 
finger measuring 1.95 mm in length and 25 µm width and spacing) with two electrical probe 
pads on the wafer using physical vapor deposition (PVD) and ultraviolet (UV) photolithography 
(Figure 1b & 1c).   The high-aspect-ratio VANTAs were subsequently grown on the IDE 
patterned iron layer using a chemical vapor deposition (CVD) method followed by an amorphous 
carbon infiltration process for structural support according to our previous work (Figure 1d) 
(Brownlee et al., 2017; Marr et al., 2015). The VANTA IDEs exhibited a height to width ratio of 
approximately 3 to 1 as the CNT height measured approximately 75 µm.  After IDE fabrication, 
anti-CIP2A Ab was attached to the surface and used to capture CIP2A antigen (Ag) (Figure 1e 
and materials and methods section in supplemental section). Prior to electrochemical sensing 
tests in the active solution, the electrical resistances of the two finger combs of the VANTA IDE 
were measured with 10-20  resistance across a contact pad (corner to corner).  The VANTA 
IDEs were next treated with O2 plasma to remove the carbon floor between the fingers of the 
IDE created from the amorphous carbon deposition process (see Methods and Materials section). 
After this O2 plasma etch, an infinitely high resistance between the two distinct finger combs was 
observed (i.e. no electrical shorting across the IDE fingers).   This O2 plasma treatment also 
enhances the surface wettability of the CNTs so that the static contact angle changes from ~110 º  
(hydrophobic; see Marr et al., 2015) to ~69 º (hydrophilic; see Fig. S3 in Supplemental 
Information). Such an oxygenated, hydrophilic surface improves the penetration of aqueous 
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solutions into the porous VANTA structure and consequently enhances the biofunctionalization 
and biosensor sensitivity (Marr et al., 2015, Banks and Compton, 2006; Claussen et al., 2012). 
The general dimensions of VANTA IDEs are shown in Figure 1f, while the highly porous and 
defect-rich nature of the VANTA structures was observed with field-effect scanning electron 
microscopy (FESEM) (Figure 1g, 1h). The high resolution FESEM images revealed individual 
nanotubes as well as the carbon matrix binding along the sidewall of the VANTAs. The 
entanglement of amorphous carbon and VANTAs resulted in mechanically stable structures 
during subsequent biofunctionalization and electrochemical sensing. Raman spectra revealed a 
G-band (~1590 cm
-1
), and 2D-band (~2700 cm
-1
), which correlates well with the spectra 
commonly associated with CNTs (Figure 1i and materials and methods section in 
supplemental section).  Moreover, the presence of the D-band (~1350 cm
-1
) and its high 
intensity relative to the G-peak intensity (ID/IG~0.94) indicates a high quantity of superficial 
carbon defects (Mu et al., 2006; S.Costa et al., 2008). Such carbon defects are indicative of edge 
plane sites that have been shown to increase heterogeneous charge transfer during 
electrochemical sensing and deposition (Banks and Compton, 2006; Claussen et al., 2012).  
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Figure 1. Fabrication process steps of the VANTA IDEs. (a) PVD of 50 nm Al2O3 (purple) on a 
Si/SiO2 wafer (grey) followed by spin coated AZ3330 photoresist (red); (b) UV lithographic 
patterning of the IDE footprint within the photoresist followed by PVD of a 7 nm thick iron (Fe) 
layer; (c) photoresist development and exposing Fe IDE pattern; (d) CVD growth of the 
VANTAs from the Fe pattern followed by in situ amorphous carbon infiltration; (e) schematic 
diagram showing anti-CIP2A Ab bound to the VANTA IDE with CIP2A Ag; (f) optical image 
showing the scale of a representative VANTA IDE next to a ruler (the numerical unit values on 
the ruler are in centimeters) (g) & (h) FESEM images of representative VANTAs from the IDE 
devices in both low and high magnification respectively; (i) Raman spectra of the VANTAs 
showing characteristic CNT D and G peaks. 
 
 The electrochemical reactivity of the VANTA-IDEs was next characterized with both 
ferricyanide cyclic voltammetry (CV) and EIS (see Figure 2 and Supplemental Information). 
Well-defined anodic and cathodic peak currents (Ip) were obtained across a range of scan rates (5, 
10, 25, 50, and 100 mV s
-1
) due to the ferricyanide (Fe
3+
/Fe
2+
) redox couple (Figure 2a). These 
peak currents display a linear relationship, indicating reversible behavior, when plotted against 
the square-root of the voltage scan (Randles-Sevcik plot) (Figure 2b).  It should also be noted 
that a minor redox peak appears near -0.41 V due to the Fe/Fe
2+
 redox couple.  This redox couple 
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is present in the electrode due to the use of a Fe metal catalyst that seeds the growth of CNTs 
during the CVD synthesis process.  Moreover, the peak-to-peak separation  Δ p) values range 
from 0.10 V to 0.21 V across the acquired scan rates. Such low ΔEp values are indicative of fast 
and reversible heterogeneous electron charge transfer at room temperature and are significantly 
lower to ferricyanide electrochemistry electron transfer rates acquired from the basal planes of 
highly oriented pyrolytic graphite (Δ p 630 mV). These Δ p values compare favorably with 
similar CNT-based electrodes where aligned MWCNTs electrodes, horizontally oriented 
SWCNT paper, and verticall  oriented SWCN  arra s report Δ p values of 0.23 V, 0.096 mV, 
and 0.090 mV respectively.(Claussen et al., 2011; Li et al., 2002; Moore et al., 2004) The 
effective electroactive surface area  A ≈ 0.00513 mm2) of the VANTAs was calculated by 
incorporating the recorded Ip values into the Randles-Sevcik equation (Eq. 1),  
   (         
 ) 
 
  
 
  
 
         (1) 
where n is the number of electrons transferred by the Fe
3+
/Fe
2+
 redox couple (n=1), v is the scan 
rate (v =100 mV/s), D is the diffusion coefficient (D = 7.20  10-6 cm2/s), and C is the analyte 
concentration (C = 5 mM).  An electroactive surface area of this value results in approximate 1% 
active sites (i.e., the surface area where heterogeneous charge transport occurs; active site is the 
ratio between electroactive surface area and geometric area) for the Fe
3+
/Fe
2+
 redox couple 
estimated during ferricyanide cyclic voltammetry (CV) at a scan rate of 50 mV/s.  Such values 
are greater than previous reports which demonstrate approximately 0.4% active sites (Salinas-
torres et al., 2011). Thus, the porous nature of the VANTA IDEs significantly raises the 
electroactive surface area above a conventional solid or planar IDE sensor (Laureyn et al., 2001) 
and provides more carbon-carbon defects or active sites than conventional CNT electrodes 
(Banks et al., 2005, 2004). 
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To further demonstrate the impedimetric response of the VANTA IDEs, EIS ferricyanide 
measurements were conducted in the frequency range from 0.1 Hz to 1 MHz using increased 
concentrations of KCl (from 1.0 µM to 1.0 M KCl) (Figure 2d-2e). These faradaic EIS 
measurements can be represented as a three component equivalent circuit (i.e., a 3 electrode 
potentiometric set-up with a reference electrode—the sensing modality used to electrochemically 
characterize the VANTA IDEs) where Cdl is the double layer capacitance, Rs is ionic resistance 
from electrolyte , and Cdi is the dielectric capacitance from the electrolyte (Zou et al., 2006). At 
lower frequencies (0.1 Hz to 10 Hz), Cdl governs the overall impedance change, from which 
lower KCl concentration leads to a higher amplitude and lower phase shift. At the intermediate 
frequency region (10 Hz to 10 KHz), the conduction/resistance of ions in solution, Rsol, 
dominates the impedance.  At higher frequencies (10 KHz to 1 MHz), the dielectric capacitance 
supersedes the impedance, resulting in a higher phase shift at lower KCl concentrations (Zou et 
al., 2006). These results (Figure 2d, 2e) indicate how each component of VANTA IDEs respond 
to the change of KCl concentrations in the electrolyte. In addition, the VANTA IDEs displayed 
increased sensitivity to KCl concentrations changes as compared to conventional 2D planar IDEs 
under similar conditions (Figure 2f)(Laureyn et al., 2001), corroborating the high sensitivity of 
the VANTA IDEs in subsequent immunosensing.  
11 
 
 
Figure 2. Electrochemical testing of VANTA IDE devices: (a) Cyclic voltammetry (CV) at scan 
rates of 10, 25, 50, 75, and 100 mV/s; (b) Current density vs. the square root of the scan rate; (c, 
d, e) VANTA IDEs are characterized by sensing various concentrations of KCl, and the resulting 
(c) Nyquist plots, (d) impedance, and (e) phase change vs. frequency were plotted as well as (f) 
double layer capacitance and phase angle at 100 KHz versus KCl concentration.  
2.2 Biological characterization of the VANTA IDE 
 
Prior to immunosensing, immobilization of the anti-CIP2A Ab onto the VANTA IDEs 
was confirmed via fluorescence imaging (Figure 3).  To visualize the successful loading of Ab a 
fluorescein isothiocyante (FITC)-tagged, secondary Ab was used to bind the primary Ab, thus 
relating fluorescence to the amount of anti-CIP2A Ab on the VANTA IDE surface (positive 
control) (see Supplemental Information). To evaluate non-specific binding of the FITC-tagged 
Ab with the VANTA IDE surface, a negative control was performed in which the FITC-tagged 
Ab was incubated with the VANTA IDEs in the absence of primary Ab surface 
functionalization.  The negative control experiment resulted in negligible VANTA fluorescent 
labeling (Figure 3a) as compared to the positive control.  The positive control experiment did 
result in measurable VANTA fluorescence labeling (Figure 3b). Results for the positive and 
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negative Ab loading experiments are compiled in Figure 3c where a histogram compares the 
FITC-fluorescence intensities (%) of the negative and positive controls to samples without any 
biofunctionalization. The result proves the successful loading of Ab onto the surface of the 
VANTA IDEs. 
 
Figure 3. Fluorescence monitoring of Ab-Ag binding to the VANTA IDEs. (a) Fluorescence 
emitted from the VANTA IDEs functionalized with FITC-tagged secondary Ab only 
(fluorescence OFF), and (b) with both primary CIP2A antibodies and FITC tagged secondary 
antibodies (fluorescence ON) (c) Comparative histogram depicting the fluorescence emission 
from the blank, negative control, and positive control VANTA IDEs respectively (n = 3). In (b & 
c), bright dots were residual debris/clustered fluorescence tagged antibody. 
 
2.3 Immunosensing of CIP2A in PBS and saliva 
To perform immunosensing of CIP2A (Figure 4), the VANTA IDEs were functionalized with 
anti-CIP2A Ab and then incubated with increasing concentrations of CIP2A Ag. EIS 
measurements revealed that the immunosensor was capable of sensing CIP2A across a wide 
concentration range from 5 pg/mL to 400 pg/mL in phosphate buffer solution (PBS; see 
calibration plots in Figure 4a) and from 1-100 pg/ l in saliva s pernatant  Figure 4a & 
Supplemental Information . Figure 4b presents the Nyquist plot of impedance measurements 
for the detection of CIP2A in saliva supernatant. It should be noted that the magnitude of each 
Nyquist plot (i.e., the radius of the first half circle, Figure 4b) increases with increasing CIP2A 
concentration.  The normalized percent change of charge transfer resistance, Rct, was calculated 
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and plotted versus concentrations of CIP2A (Figure 4a,4c,4d). The linear CIP2A sensing range 
of the VANTA IDE immunosensor (5-400 pg/ml in PBS and 1-100 pg/ l in saliva  was 
calculated using regression analysis of the normalized charge transfer resistance versus the 
functionalized CIP2A concentration plots. The gray shaded area in the plot (Figure 4a) indicates 
the sensing range of a typical human CIP2A ELISA kit (0.156-10 ng/mL)(Mybiosource, 2013); 
the VANTA IDE sensing platform demonstrates higher sensitivity and a lower sensing range in 
both PBS and saliva supernatants than the corresponding ELISA. Functionalized VANTA IDEs 
were also tested in saliva with increased incubation times (30, 45, 60, 90, and 120 mins) and 
increased BSA concentrations (0.5%, 1% and 2%), from which the impedance measurements 
indicated minimal interference/non-specific adsorption from BSA proteins and high stability in 
the complex saliva matrix (see Figure 4d).  These experiments show that the biofunctionalized 
VANTA IDEs are relatively resilient to non-specific adsorption of protein and selective to 
CIP2A with negligible interference from electroactive species found endogenously in saliva 
supernatant.  This implies the feasibility of applying VANTA IDEs toward early stage detection 
of oral cancers in actual patient saliva samples. 
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Figure 4. CIP2A calibration plots with the anti-CIP2A VANTA IDEs. (a) Functionalized 
VANTA IDEs were tested in PBS and saliva with sequential CIP2A concentration increases of 
0.1, 1, 10, 100, 200, 400, 500, and 750  pg/ml in PBS and 0.1, 1, 5, 10, 50, 100, 200, 500, 750 
pg/ml  in saliva. The first data points are acquired as a baseline without CIP2A. Grey shaded 
region shows the sensing range of a typical human CIP2A ELISA kit. (b) CIP2A Nyquist plots 
acquired in saliva supernatant. (c) CIP2A calibration plots of anti-CIP2A functionalized VANTA 
IDEs tested in saliva. Four VANTA IDEs were tested and the standard deviations are plotted to 
indicate the repeatability and reproducibility (n = 4).  Regression analysis reveals the linear 
sensing range (red dots, between 1 and 100 pg/ml). (d) The anti-CIP2A functionalized VANTA 
IDEs were also tested in saliva with increased incubation times and increased BSA 
concentrations.   
 
2.4 Statistical analysis and model fitting 
To better explain the difference in range of sensing activity between the two sample 
mediums, the calibration curves for CIP2A detection in saliva and PBS were both fit using non-
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linear regression analysis using the Hill Equation (see Figure S1 in Supplemental 
Information ).  This sigmoidal curve fit indicates the biosensor performance characteristics and 
enables a better understanding of the binding activity between Ab and Ag within different 
environments (Akai et al., 2004; Crawford et al., 2012; Rath and Panda, 2015).  The dissociation 
constant (KD), or Ab affinity to Ag, was calculated for the biosensor operating in both saliva and 
PBS via the Hill Equation (see Methods). The PBS sensing data resulted in a KD value of 82 
pg/ml with a Hill coefficient of 0.98 (or ~ 1 which is indicative of independent binding).  
However, in saliva the KD value was determined to be 13 pg/ml (higher Ab affinity to Ag than in 
PBS) with a Hill coefficient of 1.62 (indicative of slight positive cooperative binding).  The 
primary governing factors that control Ab-Ag binding within an aqueous medium are the pH, salt 
type, temperature, and ionic strength of said medium (Igawa et al., 2010; Zhao et al., 2012). In 
the case of this reported VANTA IDE, the decreased KD value or increased antibody affinity to 
CIP2A Ag and higher level of cooperative binding displayed during biosensing in the saliva 
supernatant matrix was likely a result of a more optimal pH, salt type, and ionic strength in the 
saliva solution than in PBS.  It is also worth noting that saliva supernatant was used in these 
experiments so that non-specific absorption from high molecular weight proteins and cellular 
matter (which could reduce biosensor sensitivity) was minimized as these particles were 
removed during the centrifugation process (Mohamed et al., 2012). The biosensor detection limit 
was estimated from the linear portion of the Hill Equation calibration fit (note the calibration fit 
includes an initial stationary stage, linear sensing stage, and saturation stage – Figure S1).  
Subsequently the CIP2A detection limit in both PBS and saliva, 4.69 pg/ L and 0.24 pg/ l 
respectivel ,  ere acq ired fro  t e intersection  et een t e linear trend line of t e Hill 
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 q ation cali ration fit and t e x-axis   sing 3 ti es t e standard deviation of t e  ackgro nd 
signal acq ired  efore CIP2A spiking or 3σ g idelines . (Figure 4a, 4c). 
The electrical/electrochemical behavior of the VANTA IDE immunosensor was further 
evaluated using an equivalent circuit model based on previous reports for IDEs operated in a 
faradaic EIS sensing modality (i.e., a 2-electrode potentiometric set-up without a reference 
electrode—the sensing modality used herein for immunosensing) (Ding et al., 2017). The 
eq ivalent circ it odel  as created for t e VAN A ID   iosensors    connecting t o constant-
p ase-ele ents in parallel  it  a resister  CPE-R  in series  it  Rs  i.e.,   lk sol tion ionic 
resistance according to  andles  odel38   Figure S2 in Supplemental Information . Since t e 
VAN As are co prised of a poro s  aterial, t o se icircle patterns are o served in t e N q ist 
plot   vgenij Barso kov, 2005; P nit  K  ar et al., 2015 ,   ic  correspond to t o CP s fro  
t e eq ivalent circ it si  lation.   e parallel co  ination of CPE1 and R1 indicates t e 
geo etric capacitance of t e ID  sensor and t e c arge transfer resistance of t e fil  la er.   e 
CPE2 and R2 co ponents represent t e capacitance and resistance at t e interface  et een t e 
fil  and t e sol tion  Martin et al., 2017 . Figure S2 presents a co parison of t e experi ental 
i pedance  Nyquist plot  and si  lated res lt  sing t e circ it  odel for 0.1 pg/ L of 
concentration of A  f nctionalization, clearl  de onstrating close si ilarit . VAN A ID s 
ex i it an Rs of 100 Ω, R2 of 2000 Ω and R3 of 1100 Ω,   ile CPE1 and CPE2  ave n val es of 
0.95 and 0.80 respectivel , indicating CPE1 acts  ore like a capacitor   ile CPE2 is  ore like a 
resistor.  itting experi ental data to t e eq ivalent circ it reveals  o  eac  co ponent  e aves 
electricall  in t e electrol te and c anges  it  t e increase of CIP2A concentration. In addition, 
it proves t at t e c arge transfer resistance  as responsi le for t e detection of CIP2A. 
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3. Conclusion 
In concl sion, t is  ork de onstrated t e first  se of VAN A ID s for electroc e ical 
 iosensing of CIP2A. It   ilds  pon t e recent  od  of researc  t at  as de onstrated t e  se of 
VAN A interdigitated str ct res for a  ide variet  of applications incl ding flexi le capacitive 
sensors for  eara le strain and force  onitoring  Ki  et al., 2013 , solid-state  icro capacitors 
 C io  et al., 2013; Hsia et al., 2014 , and electrostatic torsional act ators  C oi et al., 2012 . 
  e VAN A ID s developed  erein  ere f nctionalized  it  anti-CIP2A Ab and demonstrated a 
 ide linear sensing range  et een 5 pg/ L and 400 pg/ L, in   ffer  it  a detection li it of 
4.69 pg/ L for CIP2A Ag, a ke  diagnostic  io arker expressed in saliva d ring t e earl  stages 
of oral cancer.  Moreover, t e sensor de onstrated t e capa ilit  of detecting CIP2A in saliva 
s pernatant  it  a sensing range of 1-100 pg/ l and detection li it of 0.24 pg/ l  it o t t e 
need for sa ple pre-la eling or pre-concentration tec niq es.   is detection li it and sensing 
range is   c  lo er t an t e detection range  0.156 ng-10 ng/ l  reported for co  ercial 
   an CIP2A  LISA kits  M  ioso rce, 2013 . Moreover, t e total sensing ti e req ired for 
t is  iosensor is less t an 35  in tes  incl ding sa ple inc  ation and signal acq isition ti e .  
Hence, t is  ork de onstrates great pro ise in providing a potential platfor  tec nolog  for 
oral cancer detection at t e POC and/or potential for detecting ot er target anal te in a saliva 
 atrix.  Moreover, CIP2A prod ction is also linked to ot er cancers s c  as  reast and 
 elano a cancers, and t erefore t e VAN A ID s developed  erein co ld conceiva l   e 
 odified for  se in t e  lood or tiss e atrix for  ltiple cancer screening experi ents. 
Indeed, t is  ork not onl  paves t e  a  for t e exploitation of VAN A ID  devices as 
i   nosensors,   t also for electroc e ical  iosensing in general.   e 3D VAN A str ct res 
 ere cond cive to A   iof nctionalization and did not interfere  it  i   nological  inding 
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 otifs   ile still providing gaps in t e  iorecognition la er for significant c arge transfer to 
occ r d ring  IS  eas re ents.  Hence t e VAN A-ID s ena le Ag detection  it o t t e need 
for secondar  A /nanoparticle la els.  Furthermore, the use of faradaic EIS performed with the 
redox probe [Fe(CN)6]
3−/4−
 eliminated the need for a reference electrode or a 3-electrode 
electrochemical set-up (Ohno et al., 2013).  The elimination of 3-electrode patterning and a 
redox material makes these VANTA-IDEs well-suited for miniaturization, large scale fabrication 
and potential incorporation into microfluidic channels for multiplex electrochemical sensing of a 
wide variety of target analytes from a single sample.  Moreover, the use of electrochemical 
devices enables POC sensing as only minimal equipment such as a portable potentiostat (similar 
to a glucometer) can be used by non-technical staff to operate the screening tests. Hence 
electrochemical devices can circumvent the challenges associated with fluorescence/optical 
based sensors that require complex equipment/processes (e.g., fluorescence microscopes, pre-
labeling steps) and that can be impeded by turbid, optically dense or autofluorescent biological 
samples (Bandodkar et al., 2015). Furthermore, the fabrication protocol for 3D CNT electrodes 
developed herein could be applied to emerging fields that have incorporated CNTs into 
numerous electrochemical applications including sensors, fuel cells, actuators, and energy 
harvesters (Hu et al., 2010; Kong and Chen, 2014; Rowe et al., 2011). 
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Highlights 
 
 The first electrochemical immunosensor for monitoring CIP2A, a salivary oncoprotein. 
 3D vertically aligned carbon nanotubes arrayed in a 2D interdigitated electrode pattern provides a 
high surface area environment for sensitive electrochemical sensing. 
 The biosensor demonstrated high selectivity and sensitive in the saliva supernatant matrix with a 
CIP2A detection limit of 0.24 pg/ml and a sensing range of (1 –100 pg/mL) 
 
 
